| Dr Ryan Purkhiser, MD | |
|
901 W Ben White Blvd, Austin, TX 78704-6903 | |
| (512) 447-2211 | |
| Not Available |
| Full Name | Dr Ryan Purkhiser |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 7 Years |
| Location | 901 W Ben White Blvd, Austin, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427584689 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | S8635 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St David's South Austin Medical Center | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ipc Healthcare Services Of Texas Pllc | 3971824939 | 143 |
News Archive
A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.
New findings, led by neuroscientists at the University of Bristol and published this week in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older.
A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
› Verified 7 days ago
| Entity Name | Ipc Healthcare Services Of Texas Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023403011 PECOS PAC ID: 3971824939 Enrollment ID: O20150603001409 |
News Archive
A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.
New findings, led by neuroscientists at the University of Bristol and published this week in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older.
A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
› Verified 7 days ago
| Entity Name | Lonestar Pat Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811594203 PECOS PAC ID: 9335559871 Enrollment ID: O20201111002742 |
News Archive
A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.
New findings, led by neuroscientists at the University of Bristol and published this week in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older.
A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan Purkhiser, MD 901 W Ben White Blvd, Austin, TX 78704-6903 Ph: (512) 447-2211 | Dr Ryan Purkhiser, MD 901 W Ben White Blvd, Austin, TX 78704-6903 Ph: (512) 447-2211 |
News Archive
A novel partnership between Massachusetts General Hospital and Massachusetts Institute of Technology is addressing three major challenges in clinical medicine – improving the diagnosis of disease, developing new approaches to prevent and treat infectious and autoimmune diseases, and developing more accurate methods of diagnosing and treating major neurodegenerative and psychiatric diseases. While individual collaborations between MGH and MIT investigators are nothing new, this formalized strategic partnership is designed to accelerate the development of diagnostic tools and therapies.
New findings, led by neuroscientists at the University of Bristol and published this week in the journal Neurobiology of Aging, reveal a novel mechanism through which the brain may become more reluctant to function as we grow older.
A recent review paper published in the MDPI's journal Viruses highlights how available vaccines may be effective in protecting individuals against severe forms of coronavirus disease 2019 (COVID-19), but the protection against infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its transmission to others may be reduced – with consequences for community protection and herd immunity.
Orexigen® Therapeutics, Inc. and Takeda Pharmaceutical Company Limited announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.
A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
› Verified 7 days ago
Dr. Leah Barnett Staines, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 1201 W 38th St, Austin, TX 78705 Phone: 800-243-3839 | |
Holly A Cearley, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2400 Cedar Bend Dr., Austin, TX 78758 Phone: 512-901-4016 Fax: 512-901-3948 | |
Dr. Elinor Elizabeth Pisano Anspaugh, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 12221 North Mopac Expwy, Austin, TX 78704 Phone: 512-901-1000 | |
Lakshmy Vaidyanathan, M.D Hospitalist Medicare: Medicare Enrolled Practice Location: 1201 W 38th St, Austin, TX 78705 Phone: 512-659-5926 | |
Malik M Merchant, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 12221 N Mopac Expy, Austin, TX 78758 Phone: 512-901-4009 Fax: 512-901-3909 | |
Dr. Stephanie Marie Glover, M.D. Hospitalist Medicare: Medicare Enrolled Practice Location: 1201 W 38th St, Nicu 8th Floor, Austin, TX 78705 Phone: 512-324-1085 | |
Dr. Jonathan Admil Guerra Rodriguez, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 7000 North Mopac, Suite # 420, Austin, TX 78731 Phone: 512-482-0045 Fax: 512-476-9892 |